Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Viking Holdings shares dropped Tuesday as executives warned of macroeconomic "uncertainties" on the cruise operator's ...
11don MSN
Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing ...
Viking Therapeutics ( VKTX -0.30%) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may ...
Considering this and Viking's clinical trial advancements, is the stock a buy right now? Image source: Getty Images. First, let's back up and take a look at the company's story over the past year.
Investor's Business Daily on MSN12d
Viking Beats Earnings Views As Travel Stocks RetreatViking clears Q4 views, provides an update on cruise bookings. Shares ease as travel stocks fall on demand warnings.
Wednesday, Goldman Sachs initiated coverage on Viking Holdings (NYSE:VIK) stock, a $20.9 billion market cap cruise operator, with a Neutral rating and a 12-month price target of $49.00. The firm's ...
The stock surged more than 120% in one trading session after Viking spoke about VK2735, a candidate that works in the same way as big pharma Eli Lilly's blockbuster drugs Mounjaro and Zepbound.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback